Beam Therapeutics Inc. (BEAM): Revenue
$139.74M
Year ended 2025-12-31
$156.03M
Trailing 12 months to 2026-06-30
+31.9%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $139.74M | +120.0% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $63.52M | -83.2% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $377.71M | +520.0% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $60.92M | +17.5% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $51.84M | n/m | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $24.0K | +33.3% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $18.0K | n/a | 2022-02-28, From 2019-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Beam Therapeutics Inc. (BEAM) | 2025-12-31 | $139.74M | +120.0% |
| Monte Rosa Therapeutics, Inc. (GLUE) | 2025-12-31 | $123.67M | +63.5% |
| Atara Biotherapeutics, Inc. (ATRA) | 2025-12-31 | $120.77M | -6.3% |
| Ginkgo Bioworks Holdings, Inc. (DNA) | 2025-12-31 | $170.16M | -25.1% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $170.44M | +104.5% |
| Agenus Inc (AGEN) | 2025-12-31 | $114.20M | +10.4% |
| ImmunityBio, Inc. (IBRX) | 2025-12-31 | $113.29M | +668.3% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $178.03M | +195.3% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $109.16M | n/m |
Compare BEAM, GLUE, ATRA, DNA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗